Signatera Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in...